ADI Launches the Alzheimer’s Disease Atlas
Access the world's first of its kind platform highlighting how countries diagnose, treat and support people living with dementia.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
Highlights from the National Dementia Plan Pan Regional Workshop 2026
Government representatives, dementia associations and WHO experts gathered in London to share progress, tackle challenges and strengthen collaboration on developing and implementing effective National Dementia Plans worldwide.
ADI at AAIC 2024
ADI’s Diego Aguilar and Nick House attend the Alzheimer's Association International Conference in Philadelphia (USA), delivering key insights, conducting vital meetings and advocating for care in the era of new treatments.
Lancet Commission identifies two new risk factors for dementia and suggests 45% of cases could be delayed or reduced
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
EMA’s advisory committee (CHMP) recommends not granting marketing authorization for lecanemab
Lecanemab represents the second antibody treatment for Alzheimer’s disease to not be recommended marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Donanemab update: new Alzheimer’s disease treatment approved by the FDA
On 2 July 2024, the U.S. Food and Drug Administration (FDA) approved the marketing authorisation for Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease. Donanemab is the…
In celebration of Brazil’s journey towards a newly announced National Dementia Plan
In under a year, Brazil has made giant leaps in the development of its own National Dementia Plan, culminating in legislation signed by President Luiz Inácio Lula da Silva on 4 June, 2024. ADI revisits the journey that we have shared with our Brazilian member association, Febraz, to help make this plan a reality.
Celebrating 40 years of ADI
This year, 2024 marks the 40th year of Alzheimer's Disease International and our work to secure a future that includes greater awareness of the condition, increased access to care, post-diagnostic support,and emerging treatments as well as a achieving a world without stigma. ADI invites our global community to celebrate with us on this momentous occasion with thanks to all who have been with us on this journey over four decades.
ADI CEO highlights the global and national policy landscape at the ADI 2024 Conference
ADI CEO, Paola Barbarino took to the stage at the ADI 2024 Conference in Krákow, Poland, to highlight the global and national policy landscape on dementia, providing her perspective on the achievements of ADI in the past four decades and hopes for the future.
The 36th Global Conference of ADI – marking 2024 as a year of global insights, innovations and inspirations
In April 2024, the world's longest-running global conference on Alzheimer's disease and dementia came to Kraków, Poland, to provide the latest insights, innovations and inspirations on dementia over three days, six plenary sessions, 29 parallel sessions and eight symposiums to over 1000 delegates representing over 100 countries.